Review findings

Peptide Protocol Wiki June 3, 2026 BPC-157 Semaglutide Tirzepatide + 2 more Lifestyle 13 min read Liraglutide Side Effects: 2026 Mid-Year Update A mid-2026 review of liraglutide (Saxenda, Victoza) side effects covering GI tolerability, cardiovascular safety from LEADER, long-term post-marketing signals, and how the profile compares to semaglutide, tirzepatide, and retatrutide.

ht reduction in clinical trials • Once-weekly subcutaneous injection for improved adherence • Significant HbA1c reduction (up to 2.58% in SURPASS trials) Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) 💉 Dosing Amount 2.5 mg starting dose, escalating to 5-15 mg maintenance Frequency Once weekly Duration Ongoing (chronic therapy) Step-wise Titration 💊 Administration Route SC Schedule Once weekly Timing Same day each week, any time of day, without regard to meals ✓ Rotate injection sites 📅 Cycle Duration Ongoing (chronic therapy) Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Store refrigerated at 2-8 degrees C (36-46 degrees F) in the original carton to protect from light.

dose: 2.5 mg · cycle: Cycle · route: subcutaneous · frequency: weekly · reconstitution: reconstitution

PMID: 34186022): The study showed HbA1c reduction of 1.87% , 1.89% , and 2.07% vs 0.04% placebo The study showed body weight reduction of 7.0-9.5 kg across dose groups The study showed up to 52% of patients achieved HbA1c below 5.7% at the 15 mg dose Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) , published in New England Journal of Medicine (Jastreboff AM et al., 2022;

dose: 15 mg · timing: AM · frequency: Once Weekly

rticipants achieved 25% or more weight loss with tirzepatide 15 mg Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2) , published in The Lancet (Garvey WT et al., 2023;

dose: 15 mg · frequency: Once Weekly

Lower doses of 5 mg and 10 mg produced 15% and 19.5% weight loss respectively.

dose: 5 mg

In the SURPASS-2 head-to-head trial, tirzepatide showed greater A1C reduction and weight loss than semaglutide 1 mg.

dose: 1 mg

In the SURMOUNT-1 Phase 3 trial, participants on the highest dose (15 mg) lost an average of 22.5% of body weight over 72 weeks.

dose: 15 mg

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About Tirzepatide 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides Tirzepatide Weight Loss & Metabolism Anti-Obesity approved Tirzepatide Also known as: LY3298176, Mounjaro, Zepbound Compare with 13 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated January 29, 2026 Citations Verified TL;DR Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly.

Discard if exposed to temperatures above 30 degrees C or if the 21-day room temperature window is exceeded. ⚗️ Suggested Bloodwork ( 6 tests) HbA1c and fasting glucose When: Baseline Why: Baseline glycemic control Lipid panel When: Baseline Why: Baseline cardiovascular markers CMP with liver enzymes When: Baseline Why: Liver and kidney function Thyroid panel (TSH, free T4) When: Baseline Why: GLP-1 agonist class MTC warning Amylase and lipase When: Baseline Wh

Peptide Directory All Peptides Metabolic Anti-Obesity Anti-Aging Immune Hormonal View All Categories Directory Peptide Vendors Analytics Labs Side Effects Database Report a Side Effect Learn Start Here What Are Peptides?

Peptide Protocol Wiki June 3, 2026 BPC-157 Semaglutide Tirzepatide + 2 more Lifestyle 13 min read Liraglutide Side Effects: 2026 Mid-Year Update A mid-2026 review of liraglutide (Saxenda, Victoza) side effects covering GI tolerability, cardiovascular safety from LEADER, long-term post-marketing signals, and how the profile compares to semaglutide, tirzepatide, and retatrutide.

Tirzepatide (Mounjaro/Zepbound): Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

The most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, and constipation.

Serious risks include a boxed warning for thyroid C-cell tumors found in rodent studies.

Weight Loss & Metabolism Anti-Obesity Retatrutide 28.7% body weight loss in Phase 3 TRIUMPH-4 at 68 weeks (Dec 2025) -- see dosing, side effects, FDA approval timeline.

ht reduction in clinical trials • Once-weekly subcutaneous injection for improved adherence • Significant HbA1c reduction (up to 2.58% in SURPASS trials) Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) 💉 Dosing Amount 2.5 mg starting dose, escalating to 5-15 mg maintenance Frequency Once weekly Duration Ongoing (chronic therapy) Step-wise Titration 💊 Administration Route SC Schedule Once weekly Timing Same day each week, any time of day, without regard to meals ✓ Rotate injection sites 📅 Cycle Duration Ongoing (chronic therapy) Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Store refrigerated at 2-8 degrees C (36-46 degrees F) in the original carton to protect from light.

PMID: 37385275): The study showed mean weight reduction of 12.8% and 14.7% vs 3.2% placebo at 72 weeks The study showed HbA1c reduction of 2.1% and 2.1% vs 0.5% placebo References # Related Reading # Tirzepatide research studies and evidence Tirzepatide dosing protocols Tirzepatide side effects profile Exenatide research guide Liraglutide research guide Footnotes # Jastreboff AM, Aronne LJ, Ahmad NN, et al.

he side effects of tirzepatide?

y: Baseline pancreatic function HbA1c When: 12 weeks Why: Monitor glycemic improvement (1.87-2.58% reduction expected) 💡 Key Considerations → Missed dose within 4 days: take ASAP → Store refrigerated;

Important Considerations # Prescription medication requiring medical supervision Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 Most common adverse events are gastrointestinal (nausea, diarrhea, vomiting) Dose escalation schedule important to minimize GI side effects Key Research Findings # Efficacy and Safety of the Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial , published in The Lancet (Rosenstock J et al., 2021;

21 days at room temp (max 30C) if needed → Contraindication: Avoid with personal/family history of medullary thyroid carcinoma or MEN2 syndrome; contraindicated in pregnancy Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.